Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
Plus Therapeutics (PSTV) will present multiple data sets at the 2024 Society for Neuro-Oncology Annual Meeting in Houston, Texas, November 21-24, 2024. The presentations will focus on their leptomeningeal metastases (LM) programs, including results from the ReSPECT-LM Phase 1 clinical trial of Rhenium Obisbemeda and the FORESEE Trial of circulating tumor cells. The company will also host an educational symposium titled 'Novel Targeted Radiotherapies to Manage Leptomeningeal Metastases' featuring clinical experts discussing LM therapeutic and diagnostic programs.
Plus Therapeutics (PSTV) presenterà diversi set di dati durante il meeting annuale della Society for Neuro-Oncology che si terrà a Houston, Texas, dal 21 al 24 novembre 2024. Le presentazioni si concentreranno sui loro programmi per le metastasi leptomeningeal (LM), inclusi i risultati del trial clinico ReSPECT-LM di fase 1 con Rhenium Obisbemeda e il trial FORESEE sulle cellule tumorali circolanti. L'azienda ospiterà anche un simposio educativo intitolato 'Nuove radioterapie mirate per gestire le metastasi leptomeningeal', con esperti clinici che discuteranno dei programmi terapeutici e diagnostici per le LM.
Plus Therapeutics (PSTV) presentará múltiples conjuntos de datos en la reunión anual de la Society for Neuro-Oncology que se llevará a cabo en Houston, Texas, del 21 al 24 de noviembre de 2024. Las presentaciones se centrarán en sus programas de metástasis leptomeníngea (LM), incluidos los resultados del ensayo clínico ReSPECT-LM de Fase 1 con Rhenium Obisbemeda y el ensayo FORESEE sobre células tumorales circulantes. La empresa también organizará un simposio educativo titulado 'Nuevas radioterapias dirigidas para manejar las metástasis leptomeníngeas', con expertos clínicos que discutirán programas terapéuticos y diagnósticos para la LM.
플러스 제약(PSTV)는 2024년 11월 21일부터 24일까지 텍사스 주 휴스턴에서 열리는 신경종양학회 연례회의에서 여러 데이터 세트를 발표할 예정이다. 발표는 겹막전이(LM) 프로그램에 초점을 맞추어, Rhenium Obisbemeda의 ReSPECT-LM 1상 임상 시험 결과와 순환 종양 세포를 다룬 FORESEE 시험 결과를 포함할 것이다. 또한, 이 회사는 '겹막전이를 관리하기 위한 새로운 표적 방사선 치료법'이라는 제목의 교육 심포지움을 주최하며, 이 자리에서 임상 전문가들이 LM 치료 및 진단 프로그램에 대해 논의할 것이다.
Plus Therapeutics (PSTV) présentera plusieurs ensembles de données lors de la réunion annuelle de la Society for Neuro-Oncology qui se tiendra à Houston, Texas, du 21 au 24 novembre 2024. Les présentations se concentreront sur leurs programmes de métastases leptomeningeales (LM), y compris les résultats de l'essai clinique de phase 1 ReSPECT-LM avec le Rhenium Obisbemeda et l'essai FORESEE sur les cellules tumorales circulantes. L'entreprise organisera également un symposium éducatif intitulé 'Nouvelles radiothérapies ciblées pour gérer les métastases leptomeningeales', avec des experts cliniques discutant des programmes thérapeutiques et diagnostiques concernant la LM.
Plus Therapeutics (PSTV) wird während des jährlichen Treffens der Society for Neuro-Oncology, das vom 21. bis 24. November 2024 in Houston, Texas, stattfindet, mehrere Datensätze präsentieren. Die Präsentationen werden sich auf ihre Programme zu leptomeningealen Metastasen (LM) konzentrieren, einschließlich der Ergebnisse der ReSPECT-LM Phase-1-Studie mit Rhenium Obisbemeda und der FORESEE-Studie zu zirkulierenden Tumorzellen. Das Unternehmen wird auch ein Bildungs-Symposium mit dem Titel 'Neue gezielte Strahlentherapien zur Behandlung leptomeningealer Metastasen' veranstalten, bei dem klinische Experten über therapeutische und diagnostische Programme für LM diskutieren werden.
- Multiple data presentations scheduled at a major industry conference (SNO)
- Phase 1 clinical trial results to be presented for Rhenium Obisbemeda in LM treatment
- Educational symposium featuring prominent medical experts
- None.
Insights
This conference presentation news is classified as not impactful for investors. While the company will be presenting clinical trial data at the SNO Annual Meeting, the article only announces future presentations without revealing any actual results or data that could impact investment decisions.
The presentations will cover Phase 1 trial results of Rhenium Obisbemeda and data from the FORESEE Trial, but since this is just an announcement of future presentations rather than the actual data disclosure, it does not warrant immediate investor attention. Any material information from these presentations would be more relevant when actually presented at the conference.
Company will present results from the ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for leptomeningeal metastases (LM) and discuss its plan for continued clinical development
Company will present results from the FORESEE Trial of circulating tumors cells for improved diagnosis and disease monitoring of LM
Company to host an educational symposium featuring clinical experts discussing LM and Plus’ recent announcements for its LM therapeutic and diagnostic programs
AUSTIN, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will have multiple opportunities to present data at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting November 21-24, 2024 in Houston, Texas.
Data presentations and symposium include:
Presentations:
| Title | Rhenium (186Re) Obisbemeda (rhenium nanoliposome,186RNL) for the treatment of leptomeningeal metastases (LM): Summary of the Phase 1 dose escalation study and Phase 2 administered dose selection (CTNI-63) |
| Presenter | Andrew Brenner, M.D., Ph.D. |
| Date/Time | Friday, 22 November 2024, 7:30-9:30 p.m. CST |
| Location | Hall B3 |
| Title | CSF Tumor Cell (CSF-TC) Detection, Quantification and Biomarker assessment helps in clinical management of breast cancer and Non-Small Cell Lung cancer patients having Leptomeningeal Disease (BIOM-70), (FORESEE Study, NCT05414123) |
| Presenter | Priya Kumthekar, M.D. |
| Date/Time | Sunday, 24 November 2024, 10:15-11:45 a.m. CST |
| Location | Grand Assembly B; Abstract Session - Clinical Trials - Non-Immunologic |
| Title | The Oncogenic Flip in Patients with Leptomeningeal Metastatic Disease (LMD): Longitudinal Detection in Cerebrospinal Fluid Tumor Cells (CSF-TCs) Reveals Implications for Differential Treatment of the LMD Tumor (BIOM-69) |
| Presenter | Arushi Tripathy, M.D., University of Michigan Medical School (Neurosurgery PGY-4) |
| Date/Time | Friday, 22 November 2024, 7:30-9:30 p.m. CST |
| Location | Hall B3 |
LM Educational Symposium:
The Company will be hosting an educational symposium titled, “Novel Targeted Radiotherapies to Manage Leptomeningeal Metastases” on Saturday, November 23, 2024, at 12:45pm-1:45 p.m. CST at the George R. Brown Convention Center, Room 351. Speakers include:
- Priya Kumthekar, M.D., Associate Professor of Neurology and Hematology/Oncology, Northwestern University Medical School (Moderator)
- Jonathan Yang, M.D., Ph.D., Associate Vice Chair for Clinical Research and Developmental Therapeutics, Department of Radiation Oncology, Director of Clinical Research, NYU Langone Health’s Perlmutter Cancer Center
- Andrew Brenner, M.D., Ph.D., Professor and Kolitz / Zachry Endowed Chair Neuro-Oncology Research; Co-Leader, Experimental and Developmental Therapeutics Program, University of Texas Health, Science Center at San Antonio
About Leptomeningeal Metastases (LM)
LM is a rare complication of cancer in which the primary cancer spreads to the cerebrospinal fluid (CSF) and leptomeninges surrounding the brain and spinal cord. All malignancies originating from solid tumors, primary brain tumors, or hematological malignancies have this LM complication potential with breast cancer as the most common cancer linked to LM, with 3
About Rhenium (186Re) obisbemeda
Rhenium (186Re) obisbemeda is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe and convenient manner. Rhenium (186Re) obisbemeda has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. Rhenium (186Re) obisbemeda is being evaluated for the treatment of recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit https://plustherapeutics.com/.
Cautionary Statement Regarding Forward-Looking Statements
This presentation contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of rhenium (186Re) obisbemeda including the ability of rhenium (186Re) obisbemeda to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM, ReSPECT-LM and ReSPECT-PBC and increase of ten o, clinical trials; possible negative effects of rhenium (186Re) obisbemeda; the continued evaluation of rhenium (186Re) obisbemeda including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms, and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2023, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Charles Y. Huang, MBA
Director of Capital Markets and Investor Relations
Office: (202)-209-5751 | Direct (301)-728-7222
chuang@plustherapeutics.com
FAQ
When will Plus Therapeutics (PSTV) present at the 2024 SNO Annual Meeting?
What clinical trial results will Plus Therapeutics (PSTV) present at SNO 2024?
What is the topic of Plus Therapeutics' (PSTV) educational symposium at SNO 2024?
